Kura Oncology Inc. [KURA] moved down -15.54: Why It’s Important



Kura Oncology Inc. [NASDAQ: KURA] closed the trading session at $14.02 on 11/24/21. The day’s price range saw the stock hit a low of $12.32, while the highest price level was $14.745. The company report on November 24, 2021 that SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura Oncology, Inc. – KURA.

Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. (“Kura” or the “Company”) (NASDAQ: KURA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


The investigation concerns whether Kura and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

The stocks have a year to date performance of -57.07 percent and weekly performance of -18.58 percent. The stock has been moved at -39.44 percent over the last six months. The stock has performed -18.35 percent around the most recent 30 days and changed -26.02 percent over the most recent 3-months.

If compared to the average trading volume of 547.46K shares, KURA reached to a volume of 6675632 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Kura Oncology Inc. [KURA]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KURA shares is $45.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KURA stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Credit Suisse have made an estimate for Kura Oncology Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on May 05, 2021. While these analysts kept the previous recommendation, Credit Suisse raised their target price to Outperform. The new note on the price target was released on April 26, 2021, representing the official price target for Kura Oncology Inc. stock. Previously, the target price had yet another raise from $40 to $45, while H.C. Wainwright kept a Buy rating on KURA stock.

The Average True Range (ATR) for Kura Oncology Inc. is set at 0.99 The Price to Book ratio for the last quarter was 1.74, with the Price to Cash per share for the same quarter was set at 8.04.

KURA stock trade performance evaluation

Kura Oncology Inc. [KURA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -18.58. With this latest performance, KURA shares dropped by -18.35% in over the last four-week period, additionally sinking by -39.44% over the last 6 months – not to mention a drop of -61.43% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KURA stock in for the last two-week period is set at 25.03, with the RSI for the last a single of trading hit 17.76, and the three-weeks RSI is set at 30.07 for Kura Oncology Inc. [KURA]. The present Moving Average for the last 50 days of trading for this stock 18.24, while it was recorded at 16.27 for the last single week of trading, and 22.35 for the last 200 days.

Kura Oncology Inc. [KURA]: An insightful look at the core fundamentals

Return on Total Capital for KURA is now -21.56, given the latest momentum, and Return on Invested Capital for the company is -21.17. Return on Equity for this stock declined to -21.60, with Return on Assets sitting at -20.16. When it comes to the capital structure of this company, Kura Oncology Inc. [KURA] has a Total Debt to Total Equity ratio set at 2.45. Additionally, KURA Total Debt to Total Capital is recorded at 2.39, with Total Debt to Total Assets ending up at 2.31. Long-Term Debt to Equity for the company is recorded at 1.62, with the Long-Term Debt to Total Capital now at 1.58.

Reflecting on the efficiency of the workforce at the company, Kura Oncology Inc. [KURA] managed to generate an average of -$1,007,022 per employee.Kura Oncology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 25.00 and a Current Ratio set at 25.00.

Earnings per share (EPS) analysis for Kura Oncology Inc. [KURA] stock

With the latest financial reports released by the company, Kura Oncology Inc. posted -0.42/share EPS, while the average EPS was predicted by analysts to be reported at -0.4/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -5.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for KURA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Kura Oncology Inc. go to 19.93%.

>> 7 Top Picks for the Post-Pandemic Economy <<

Kura Oncology Inc. [KURA]: Insider Ownership positions

There are presently around $1,117 million, in the hands of institutional investors. The top three institutional holders of KURA stocks are: FMR LLC with ownership of 6,224,773, which is approximately -20.236% of the company’s market cap and around 2.94% of the total institutional ownership; BLACKROCK INC., holding 5,001,416 shares of the stock with an approximate value of $83.02 million in KURA stocks shares; and AVORO CAPITAL ADVISORS LLC, currently with $66.4 million in KURA stock with ownership of nearly -3.382% of the company’s market capitalization.

Positions in Kura Oncology Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 65 institutional holders increased their position in Kura Oncology Inc. [NASDAQ:KURA] by around 6,964,927 shares. Additionally, 85 investors decreased positions by around 8,441,847 shares, while 34 investors held positions by with 51,864,272 shares. The mentioned changes placed institutional holdings at 67,271,046 shares, according to the latest SEC report filing. KURA stock had 10 new institutional investments in for a total of 728,533 shares, while 29 institutional investors sold positions of 2,400,483 shares during the same period.



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam